DK2273996T3 - Humane kardiovaskulære progenitorceller - Google Patents

Humane kardiovaskulære progenitorceller Download PDF

Info

Publication number
DK2273996T3
DK2273996T3 DK09726362.8T DK09726362T DK2273996T3 DK 2273996 T3 DK2273996 T3 DK 2273996T3 DK 09726362 T DK09726362 T DK 09726362T DK 2273996 T3 DK2273996 T3 DK 2273996T3
Authority
DK
Denmark
Prior art keywords
cells
human
population
progenitor cells
dkk1
Prior art date
Application number
DK09726362.8T
Other languages
English (en)
Inventor
Gordon Keller
Lei Yang
Steven Kattman
Original Assignee
Icahn School Med Mount Sinai
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icahn School Med Mount Sinai filed Critical Icahn School Med Mount Sinai
Application granted granted Critical
Publication of DK2273996T3 publication Critical patent/DK2273996T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0657—Cardiomyocytes; Heart cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/16—Activin; Inhibin; Mullerian inhibiting substance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/165—Vascular endothelial growth factor [VEGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/415—Wnt; Frizzeled
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells

Claims (13)

1. Population af humane kardiovaskulære progenitorceller, hvor progenitorcellerne er progenitorer af kardiomyocytter, endotelialceller, og vaskulære glatte muskelceller, og hvor progenitorcellerne udtrykker KDR, ikke udtrykker C-KIT, og ikke udtrykker VE-CADHERIN.
2. Fremgangsmåde til at frembringe humane kardiovaskulære progenitorceller, der er progenitorer af kardiomyocytter, endotelialceller og vaskulære glatte muskelceller, omfattende: (a) at dyrke humane embryoidlegemer i serumfrit medium i tilstedeværelsen af aktivin og BMP4; (b) at tilsætte DKK1 til mediet og at dyrke for at tilvejebringe en population af humane kardiovaskulære progenitorceller og eventuelt (c) at høste de humane kardiovaskulære progenitorceller fra kultur for at tilvejebringe en høstet cellepopulation; og eventuelt (d) at berige den høstede cellepopulation for kardiovaskulære progenitorceller.
3. Fremgangsmåden ifølge krav 2, hvor aktivin er aktivin A.
4. Fremgangsmåden ifølge krav 2, omfattende: (a) at dyrke humane embryoidlegemer i serumfrit medium i tilstedeværelsen af aktivin A og BMP4 i en til fire dage; og (b) at tilsætte DKK1 til det serumfrie medie og at dyrke i en til to dage.
5. Fremgangsmåden ifølge krav 2, omfattende: (a) at dyrke humane embryoidlegemer i serumfrit medium i fire dage i tilstedeværelsen af 3,0 ng/ml af aktivin A, 10,0 ng/ml af BMP4 og 5,0 ng/ml af bFGF; (b) at tilsætte 150 ng/ml af DKK1 og 10,0 ng/ml af VEGF til det serumfrie medie og at dyrke i en til to dage for at frembringe kardiovaskulære progenitorceller og eventuelt (c) at sortere for celler, der udtrykker KDR og ikke udtrykker C-KIT.
6. Fremgangsmåden ifølge krav 5, hvor sorteringen er ved immunoselektion eller flowcytometri.
7. Fremgangsmåde til at generere en population af human kardiomyocytter omfattende at dyrke humane embryoidlegemer i serumfrit medium i tilstedeværelsen af aktivin og BMP4, at tilsætte DKK1 til mediet og at dyrke for at tilvejebringe en population af humane kardiovaskulære progenitorceller, at dyrke populationen af humane kardiovaskulære progenitorceller, der udtrykker KDR og ikke udtrykker C-KIT i tilstedeværelsen af DKK1 i syv til ti dage, og at høste en population af human kardiomyocytter.
8. Fremgangsmåden ifølge krav 7, omfattende at dyrke de humane kardiovaskulære progenitorceller i tilstedeværelsen af VEGF og DKK1 .
9. Fremgangsmåden ifølge krav 8, hvor koncentrationen af DKK1 er fra 100 ng/ml til 200 ng/ml og koncentrationen af VEGF er fra 1,0 ng/ml til 50,0 ng/ml.
10. Fremgangsmåden ifølge krav 7, hvor cellerne dyrkes som monolag eller aggregater.
11. Fremgangsmåde til at generere kardiovaskulære kolonier indeholdende kardiomyocytter, endotelialceller, og vaskulære glatte muskelceller omfattende at dyrke humane embryoidlegemer i serumfrit medium i tilstedeværelsen af aktivin og BMP4, at tilsætte DKK1 til mediet og at dyrke for at tilvejebringe en population af humane kardiovaskulære progenitorceller og at dyrke de humane kardiovaskulære progenitorceller i tilstedeværelsen af VEGF, bFGF og DKK1 i tre til syv dage.
12. Sammensætning omfattende en population af humane kardiovaskulære progenitorceller som defineret i krav 1.
13. Population af humane kardiovaskulære progenitorceller som defineret i krav 1 til anvendelse i en fremgangsmåde til behandling af kardiomyocyterstatning.
DK09726362.8T 2008-03-27 2009-03-25 Humane kardiovaskulære progenitorceller DK2273996T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4004908P 2008-03-27 2008-03-27
PCT/US2009/038220 WO2009120762A2 (en) 2008-03-27 2009-03-25 Human cardiovascular progenitor cells

Publications (1)

Publication Number Publication Date
DK2273996T3 true DK2273996T3 (da) 2017-03-27

Family

ID=41114664

Family Applications (1)

Application Number Title Priority Date Filing Date
DK09726362.8T DK2273996T3 (da) 2008-03-27 2009-03-25 Humane kardiovaskulære progenitorceller

Country Status (8)

Country Link
US (2) US10077428B2 (da)
EP (1) EP2273996B8 (da)
JP (1) JP5801187B2 (da)
AU (1) AU2009228354B2 (da)
CA (1) CA2717962C (da)
DK (1) DK2273996T3 (da)
IL (2) IL208334A (da)
WO (1) WO2009120762A2 (da)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9175260B2 (en) * 2007-01-30 2015-11-03 TheUniversity of Georgia Research Foundation, Inc. Early mesoderm cells, a stable population of mesendoderm cells that has utility for generation of endoderm and mesoderm lineages and multipotent migratory cells (MMC)
EP3255142A1 (en) 2009-10-19 2017-12-13 Cellular Dynamics International, Inc. Cardiomyocyte production
US20120301443A1 (en) * 2009-12-29 2012-11-29 Cornell University Methods for developing endothelial cells from pluripotent cells and endothelial cells derived
EP2529008A1 (en) * 2010-01-26 2012-12-05 Université Libre de Bruxelles Tools for isolating and following cardiovascular progenitor cells
EP2580317B1 (en) 2010-06-13 2020-12-23 Institute of Biophysics Chinese Academy of Sciences Methods and compositions for preparing cardiomyocytes from stem cells and uses thereof
US9181529B2 (en) 2010-10-19 2015-11-10 Cellular Dynamics International, Inc. Titration of differentiation medium components
US20140045265A1 (en) * 2011-02-16 2014-02-13 Salk Institute For Biological Studies Robust and efficient differentiation of human pluripotent stem cells to multipotent vascular progenitors
US9487752B2 (en) 2011-03-30 2016-11-08 Cellular Dynamics International, Inc. Priming of pluripotent stem cells for neural differentiation
GB201109882D0 (en) 2011-06-13 2011-07-27 Cambridge Entpr Ltd Population of smooth muscle cells of specific embryonic lineages
GB201121101D0 (en) * 2011-12-08 2012-01-18 Nhs Blood & Transplant A method of preparing isolated cells and uses
JP5920741B2 (ja) * 2012-03-15 2016-05-18 ｉＨｅａｒｔ Ｊａｐａｎ株式会社 人工多能性幹細胞から心筋および血管系混合細胞群を製造する方法
CN104508121B (zh) * 2012-07-23 2018-01-19 中国科学院生物物理研究所 体外诱导多能干细胞分化为心室肌细胞的方法
WO2014192925A1 (ja) * 2013-05-31 2014-12-04 ｉＨｅａｒｔ Ｊａｐａｎ株式会社 効率的な内皮細胞の誘導方法
WO2014197421A1 (en) 2013-06-05 2014-12-11 Biotime, Inc. Compositions and methods for induced tissue regeneration in mammalian species
US10711246B2 (en) * 2013-09-13 2020-07-14 University Health Network Methods and compositions for generating epicardium cells
US11078462B2 (en) 2014-02-18 2021-08-03 ReCyte Therapeutics, Inc. Perivascular stromal cells from primate pluripotent stem cells
US10240127B2 (en) 2014-07-03 2019-03-26 ReCyte Therapeutics, Inc. Exosomes from clonal progenitor cells
GB201412554D0 (en) * 2014-07-15 2014-08-27 Cambridge Entpr Ltd In vitro mesodermal differentiation
WO2016131137A1 (en) 2015-02-17 2016-08-25 University Health Network Methods for making and using sinoatrial node-like pacemaker cardiomyocytes and ventricular-like cardiomyocytes
US10612002B2 (en) 2016-02-19 2020-04-07 University Of Washington Human pluripotent stem cell derived endocardial endothelium
WO2017147381A1 (en) * 2016-02-25 2017-08-31 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Generation of expandable cardiovascular progenitor cells
US20230377685A1 (en) 2022-04-15 2023-11-23 Aspen Neuroscience, Inc. Methods of classifying the differentiation state of cells and related compositions of differentiated cells

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874301A (en) 1994-11-21 1999-02-23 National Jewish Center For Immunology And Respiratory Medicine Embryonic cell populations and methods to isolate such populations
US5919449A (en) * 1995-05-30 1999-07-06 Diacrin, Inc. Porcine cardiomyocytes and their use in treatment of insufficient cardiac function
US20050021439A1 (en) * 1999-04-09 2005-01-27 Pinga Louis J. Arcade casino and home investment system
CA2453438C (en) * 2001-07-12 2016-04-05 Geron Corporation Cells of the cardiomyocyte lineage produced from human pluripotent stem cells
US20030082153A1 (en) 2001-10-22 2003-05-01 The Government Of The United States Of America Stem cells that transform to beating cardiomyocytes
US20060003446A1 (en) 2002-05-17 2006-01-05 Gordon Keller Mesoderm and definitive endoderm cell populations
WO2004094610A2 (en) * 2003-04-21 2004-11-04 Baylor College Of Medicine Wnt as a factor for cardiac myogenesis
US7452718B2 (en) * 2004-03-26 2008-11-18 Geron Corporation Direct differentiation method for making cardiomyocytes from human embryonic stem cells
US20050214938A1 (en) * 2004-03-26 2005-09-29 Gold Joseph D Cardiac bodies: clusters of spontaneously contracting cells for regenerating cardiac function
AU2006262329B2 (en) 2005-06-22 2011-04-07 Asterias Biotherapeutics, Inc. Differentiation of primate pluripotent stem cells to cardiomyocyte-lineage cells
CA2620567A1 (en) * 2005-06-23 2007-01-04 Mount Sinai School Of Medicine Of New York University Cardiomyocyte cell populations

Also Published As

Publication number Publication date
CA2717962A1 (en) 2009-10-01
AU2009228354B2 (en) 2015-01-22
IL208334A (en) 2015-09-24
IL208334A0 (en) 2010-12-30
JP2011517563A (ja) 2011-06-16
AU2009228354A1 (en) 2009-10-01
JP5801187B2 (ja) 2015-10-28
EP2273996A2 (en) 2011-01-19
IL240870B (en) 2019-08-29
US10077428B2 (en) 2018-09-18
IL240870A0 (en) 2015-10-29
US20090269314A1 (en) 2009-10-29
WO2009120762A3 (en) 2009-12-30
EP2273996A4 (en) 2012-02-15
CA2717962C (en) 2019-05-14
US20180362931A1 (en) 2018-12-20
US10947506B2 (en) 2021-03-16
WO2009120762A2 (en) 2009-10-01
EP2273996B8 (en) 2017-04-26
EP2273996B1 (en) 2017-02-22

Similar Documents

Publication Publication Date Title
US10947506B2 (en) Human cardiovascular progenitor cells
Cao et al. Highly efficient induction and long-term maintenance of multipotent cardiovascular progenitors from human pluripotent stem cells under defined conditions
US20210062153A1 (en) Methods and compositions for generating epicardium cells
CA2718032C (en) Method for generating primate cardiovascular progenitor cells for clinical use from primate embryonic stem cells or embryonic-like state cells, and their applications
US8507275B2 (en) Method of inducing differentiation of embryonic stem cells into hemangioblast
US11607429B2 (en) Derivation and self-renewal of ISI1+ cells and uses thereof
Davies et al. Stemistry: the control of stem cells in situ using chemistry
EP3448984A1 (en) Derivation and self-renewal of multipotent cells and uses thereof
US20210363485A1 (en) Stepwise method of producing various types of cells from pluripotent stem cells
WO2019189554A1 (ja) 心筋細胞成熟促進剤
EP2594635A1 (en) Method for generating primate cardiovascular progenitor cells for clinical and drug cells testing use from primate embryonic stem cells or embryonic-like state cells, and their applications
US20230078230A1 (en) Methods for the production of committed cardiac progenitor cells
Braam et al. SEVEN